臨床腫瘤學次世代定序儀市場規模、佔有率和成長分析：按技術、工作流程、應用、最終用途和地區 - 2025-2032 年行業預測

2023年臨床腫瘤次世代定序儀的全球市場規模估值為3.8億美元，從2024年的4.4042億美元成長到2032年的14.3395億美元，在預測期內（2025年）預計複合年成長率為15.9%從2013 年到2032 年）。

次世代定序(NGS) 為全面的基因組分析提供可擴展的高通量解決方案，正在徹底改變臨床腫瘤學。這種先進的定序技術能夠識別罕見癌症和新型癌症突變，有助於檢測家庭遺傳性癌症風險，並幫助為個別患者選擇標靶治療。 NGS 過程的關鍵是 DNA 預測定序，它執行樣品製備以獲得準確的定序結果。我們的平台透過分析原始資料對基因組變化進行分類並解釋與現有實驗和核准治療的相關性，增強了 NGS 的臨床效用。因此，NGS資料處理系統的整合對於提供個人化腫瘤治療並幫助醫療保健專業人員根據基因組見解做出明智的治療決策將變得越來越重要。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 案例研究分析

臨床腫瘤學次世代定序儀市場規模：依技術分類

• 市場概況
• 全基因組序列分析
• 全EXOME定序
• 標靶定序和定序

臨床腫瘤學次世代定序儀市場規模：依工作流程

• 市場概況
• NGS預測序
• NGS定序
• NGS資料分析

臨床腫瘤學次世代定序儀市場規模：按應用分類

• 市場概況
• 篩檢
• 散發性癌症
• 遺傳性癌症
• 伴同性診斷
• 其他診斷

臨床腫瘤學次世代定序儀市場規模：依最終用途分類

• 市場概況
• 醫院
• 診所
• 研究所

臨床腫瘤學次世代定序儀的市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Illumina, Inc.（US）
• Thermo Fisher Scientific, Inc.（US）
• F. Hoffmann-La Roche AG（Switzerland）
• Qiagen NV（Netherlands）
• Agilent Technologies, Inc.（US）
• BGI Genomics Co., Ltd.（China）
• PerkinElmer, Inc.（US）
• Oxford Nanopore Technologies, Inc.（UK）
• Pacific Biosciences of California, Inc.（US）
• Eurofins Scientific SE（Luxembourg）
• Myriad Genetics, Inc.（US）
• Guardant Health, Inc.（US）
• Natera, Inc.（US）
• Biocartis Group NV（Belgium）

結論和建議

Global Clinical Oncology Next Generation Sequencing Market size was valued at USD 380.0 million in 2023 and is poised to grow from USD 440.42 million in 2024 to USD 1433.95 million by 2032, growing at a CAGR of 15.9% during the forecast period (2025-2032).

Next Generation Sequencing (NGS) is revolutionizing clinical oncology by offering scalable, high-throughput solutions for comprehensive genomic analysis. This advanced sequencing technology enables the identification of rare and novel cancer mutations, facilitates the detection of hereditary cancer risk among family members, and informs the selection of targeted therapies tailored to individual patients. Key to the NGS process is DNA pre-sequencing, which prepares samples for accurate sequencing outcomes. Our platform enhances the clinical utility of NGS by analyzing raw data to categorize and interpret genomic alterations in correlation with existing experimental and approved treatments. Consequently, the integration of NGS data processing systems is increasingly vital for delivering personalized oncology care, empowering healthcare professionals to make informed treatment decisions based on genomic insights.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Clinical Oncology Next Generation Sequencing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Clinical Oncology Next Generation Sequencing Market Segmental Analysis

Global Clinical Oncology Next Generation Sequencing Market is segmented by Technology, Workflow, Application, End-use and region. Based on Technology, the market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing. Based on Workflow, the market is segmented into NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis. Based on Application, the market is segmented into Screening, Sporadic Cancer, Inherited Cancer, Companion Diagnostics and Other Diagnostics. Based on End-use, the market is segmented into Hospitals, Clinics and Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing (NGS) market is experiencing significant growth driven by advancements in research and technology. The rising demand for NGS technologies aligns with the growing emphasis on personalized medicine and companion diagnostics. Additionally, the expansion of NGS applications in liquid biopsy-specifically for sequencing circulating tumor DNA-promises to enhance revenue generation in the sector by facilitating non-invasive cancer profiling and real-time monitoring. Furthermore, increased funding for oncology research is contributing to the market's expansion, as innovative research programs and technological advancements continue to propel the utilization of NGS in clinical oncology settings.

Restraints in the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing market faces significant constraints primarily due to the high costs involved. Patients worldwide struggle with the exorbitant expenses associated with this advanced clinical oncology process, creating substantial barriers to access. Ongoing economic challenges and political instability in various countries raise doubts about the sustainability of public healthcare funding. Furthermore, the lack of effective and affordable cancer treatments negatively affects population health, particularly in low-income nations, leading to decreased life expectancy. The high costs of consumables and specialized equipment for treating rare cancers further exacerbate the situation, stifling market growth and limiting accessibility.

Market Trends of the Global Clinical Oncology Next Generation Sequencing Market

The Global Clinical Oncology Next Generation Sequencing (NGS) market is poised for significant growth driven by the rising adoption of NGS in liquid biopsies, which enable the non-invasive sequencing of circulating tumor DNA. This technology allows for efficient tumor profiling and real-time cancer surveillance, addressing the urgent need for innovative diagnostic solutions. The advanced capabilities of NGS have evolved to facilitate simultaneous sequencing of multiple genomes, enhancing its appeal among laboratories for routine diagnostics. Factors such as accelerated processing speed, increased sensitivity, and reduced cost per sample are further propelling the market as providers leverage NGS to advance cancer research and patient care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

Global Clinical Oncology Next Generation Sequencing Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

Global Clinical Oncology Next Generation Sequencing Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening
• Sporadic Cancer
• Inherited Cancer
• Companion Diagnostics
• Other Diagnostics

Global Clinical Oncology Next Generation Sequencing Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Laboratories

Global Clinical Oncology Next Generation Sequencing Market Size & CAGR (2025-2032)

• North America (Technology, Workflow, Application, End-use)
  • US
  • Canada
• Europe (Technology, Workflow, Application, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Workflow, Application, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Workflow, Application, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Workflow, Application, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies, Inc. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocartis Group NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations